Research on New Drugs and Drug Targets in Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 20 August 2025 | Viewed by 1316
Special Issue Editors
Interests: melanoma; in vitro tests; isobolographic analysis; natural substances; pharmacodynamic interactions
Interests: melanoma; signal transduction; targeted therapies; drug resistance; MAPK; PI3K; cAMP
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The incidence of melanoma is steadily increasing worldwide. Malignant melanomas are dangerous skin cancers, and their treatment with various cytostatics often causes side effects; moreover, their prolonged use can lead to drug resistance. Surgical excision is the main method of treatment, and in the case of metastasis or resistance, other methods of treatment are available. Understanding the mechanisms and cellular pathways of melanoma allows for the development of more effective therapies, including immune checkpoint inhibitors, targeted therapies based on signaling pathways, intrafocal therapy (for unremovable melanomas) and local therapy (for single melanomas). The treatment of metastatic or drug-resistant melanoma still represents a significant therapeutic challenge. In recent years, new drugs have been introduced to treat melanoma, but scientists are still looking for new treatment options to improve therapeutic outcomes and increase patient survival.
The purpose of this Special Issue is to present new drugs or substances with potential against melanoma. Additionally, we are interested in drug targets and their mechanisms of action on many levels, including molecular and cellular.
Dr. Paula Wróblewska Łuczka
Dr. Nicolas Dumaz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- new drugs
- drug targets
- mechanism of action
- substances with anti-melanoma potential
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
